Company intelligence / Profile preview

Tasly

Rockville, Maryland, United Statestasly.com ↗

Ownership: Private
Employees: ~10000
Development stage: Other

Overview

Tasly's lead botanical drug T89 (Dantonic) completed global Phase III trials for chronic stable angina and is approved in 24 countries (not the USA); the pipeline includes compounds at various stages up to Phase III, with oncology and cardiovascular focus. Investigational cancer small molecules (TSL1502) are in Phase II in China, a polypeptide antiviral (HEPA44) is applying for US IND, and a stem cell program completed Phase I.

Therapeutic areas: EndocrinologyInfectious DiseasesPulmonologyCardiovascularOncologyNeurology
Modalities: Herbal medicineSmall moleculePolypeptideStem cell therapyBiologic
Industry: Biotech

Drug pipeline

2 assets

5LGr

Unknown

1 more asset in the full pipeline.

Partnerships

Planned joint venture with Herbalife (announced 2017)Academic, hospital, and pharma company collaborations (various, not all public)

Beyond the preview

Go deeper on Tasly.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Tasly.